No regrets
Although it is now chasing other compounds in the clinic, Seattle Genetics Inc. has no regrets over its decision three years ago to shelve its SGN-15 first-generation antibody-drug conjugate in favor of the second-generation compound, SGN-35. Given the unmet medical need in Hodgkin's lymphoma, the company hopes it will be able to file for approval based on Phase II data.
The company reported data from an ongoing Phase I trial of SGN-35 at last week's American Society for Clinical Oncology (ASCO) meeting. Data from 38 evaluable patients with relapsed or refractory CD30-positive hematologic malignancies showed 12 objective responses (ORs), including 5 complete responses (CRs) and 7 partial responses (PRs). Fifteen patients had stable disease and 11 had progressive disease. Patients received 0.1-3.6 mg/kg of SGN-35 monotherapy every three weeks...